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To the Editor
Coronavirus disease 2019 (COVID-19) has 
emerged as a pandemic and has killed millions 
across the globe [1, 2]. This pandemic is associat-
ed with relatively higher mortality than other pre-
viously known respiratory viral infections. The 
virus is predominantly transmitted by respiratory 
droplets and incites a systemic disease. There is 
also evidence of environmental factors affecting 
disease transmission [3]. Currently, effective vac-
cines are being developed for the prevention of 
the disease. However, the treatment options are 
limited as most agents targeting the virus or im-
mune system have demonstrated limited ability 
except for systemic corticosteroids [4, 5]. 
One feature associated with severe COVID-19 
is the cytokine storm wherein there are very high 
levels of pro-inflammatory as well as anti-inflam-
matory cytokines [6]. A significant proportion 
of the individuals dying due to COVID-19 have 
cytokine storm, and high cytokine levels tend to 
persist even after the individuals start showing 
signs of recovery from the acute illness. Cytokines 
levels are also higher among individuals admitted 
to ICU who die due to COVID-19 as compared 
to those who survive the illness. Cytokine lev-
els seem to play a significant role in morbidity 
and mortality in patients with COVID-19. This 
clinical situation is similar to what is seen in pa-
tients with gram-negative sepsis. Also, it is well 
known that an individual’s immune response 
to the virus is responsible for clearance as well 
as is associated with the severity of illness. The 
innate immune response is the initial and prompt 
body mechanism for resistance against patho-
genic organisms. This is done by recognition of 
pathogen-associated molecular patterns (PAMP) 
of an infectious agent by pathogen recognizing 
receptors (PRR) like toll-like receptors (TLR). This 
immune response is the first protection against in-
fection and is considered relevant to COVID-19 as 
well. This has led to scientific thinking towards 
the use of immunomodulators in patients with 
COVID-19. One of such immunomodulatory ther-
apy is heat-killed Mycobacterium w (Mw). 
Mycobacterium w is a nonpathogenic, rapidly 
growing atypical mycobacterium and has been 
renamed as Mycobacterium indicus pranii. This 
species shares T and B cell determinants with 
Mycobacterium leprae as well as Mycobacterium 
tuberculosis. Heat-inactivated Mw has been used 
in various conditions as immunomodulators as 
it evokes antigen-specific cell-mediated immu-
nity and augments Th1 type of cross-reactive 
response. Immune response to a pathogen can be 
of Th1 or Th2 type. Th1 immune response is asso-
ciated with clearance of infection while Th2 type 
of response is associated with persistence and 
allergy response.
Following the administration through intra-
dermal route, Mw induces a potent Th1 response. 
This vaccine was initially developed for 
leprosy [7]. However, due to its immune-boosting 
effects, it has been used to prevent tuberculosis 
and treat sepsis. The intralesional vaccine is also 
being tried for the use in cutaneous warts [8]. 
Mw reduces overexpressed pro-inflammatory 
as well as anti-inflammatory cytokines. It also 
reduced mortality in established sepsis-induced 
by E.coli when added to standard therapy (anti-
biotics plus glucocorticoids). In a randomized 
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controlled study among fifty patients with sep-
sis, administration of 0.3 ml of Mw per day for 
three days (as compared to placebo) resulted 
in a statistically significant and clinically rel-
evant faster recovery (ventilator days 6 vs 9, 
p = 0.025; length of ICU stay 7 vs 12 days, p = 0.006; 
and length of hospital stay 10 vs 16 days, 
p = 0.007). However, there was no difference in 
mortality between the two groups [9]. It is thought 
to work by overcoming the immune paralysis 
in severe sepsis. There are few initial reports 
of its safety in patients with COVID-19 [10]. 
However, there are ongoing trials regarding its 
efficacy and safety in COVID-19 patients with 
varying severity levels (CTRI/2020/05/025271, 
CTRI/2020/04/024846). Mw has undergone thor-
ough preclinical and clinical studies and is now 
approved as an adjunct therapy for the manage-
ment of gram-negative sepsis in India. Its role 
in COVID-19 prevention and treatment is being 
studied, and it may emerge as a potential treat-
ment option for the same (CTRI/2020/05/025277). 
BCG vaccine, which has been used for 
prevention of tuberculosis, is another immu-
nomodulator that is being tried to prevent 
COVID-19 (NCT04534803). There are multiple 
publications regarding the community BCG vacci-
nation conferring protection from COVID-19 [11]. 
Both BCG and Mw differ in their immune re-
sponse generation by TLR agonism and ligand 
presentation. The concept of using these agents 
to modulate the innate immune response to 
confer protection and hasten recovery from var-
ious pathogens, including SARS-CoV-2, seems 
reasonable. However, the results of the ongoing 
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